Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy

Mehee Choi, Choong R. Kim, Arthur Hung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: To summarize our results of intensity-modulated radiation therapy (IMRT) for prostate adenocarcinoma after cryotherapy failure. Materials and Methods: Patients underwent IMRT with curative intent for biochemically recurrent prostate cancer after cryotherapy. Radiation was delivered to a minimum dose of 72 Gy (range, 72-81 Gy). Acute and late treatment-related gastrointestinal and genitourinary effects were scored according to Common Toxicity Criteria version 3.0. Prostate-specific antigen failure was defined by Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2006 consensus definition. Results: Nine patients were treated from 2008 to 2010. The median follow-up was 31 months (range, 15-40 months). The mean preradiotherapy prostate-specific antigen was 4.3 ng/mL (range, 1.07-15.6 ng/mL). The median elapsed time between cryotherapy and IMRT was 20.5 months (range, 8.5-56.5 months). Biochemical control was achieved in 7 patients. Two patients developed distant metastases shortly after completion of radiotherapy. No patients experienced grade 3 or higher toxicities. Conclusions: Our results suggest that high-dose IMRT after cryotherapy failure is well tolerated, without severe morbidity. The results also showed that IMRT can render a significant number of patients biochemically free of disease after initial cryotherapy. High-dose IMRT should be considered as a treatment option for these potentially salvageable cases.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalClinical Genitourinary Cancer
Volume11
Issue number2
DOIs
StatePublished - Jun 2013

Fingerprint

Cryotherapy
Prostatic Neoplasms
Radiotherapy
Prostate-Specific Antigen
Radiation Oncology
Prostate
Adenocarcinoma
Radiation
Neoplasm Metastasis
Morbidity
Therapeutics

Keywords

  • Cryotherapy
  • Intensity-modulated radiotherapy
  • Prostate cancer
  • Radiotherapy
  • Salvage therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy. / Choi, Mehee; Kim, Choong R.; Hung, Arthur.

In: Clinical Genitourinary Cancer, Vol. 11, No. 2, 06.2013, p. 85-88.

Research output: Contribution to journalArticle

@article{ca5ef0c2049e4362ae7c393476175113,
title = "Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy",
abstract = "Background: To summarize our results of intensity-modulated radiation therapy (IMRT) for prostate adenocarcinoma after cryotherapy failure. Materials and Methods: Patients underwent IMRT with curative intent for biochemically recurrent prostate cancer after cryotherapy. Radiation was delivered to a minimum dose of 72 Gy (range, 72-81 Gy). Acute and late treatment-related gastrointestinal and genitourinary effects were scored according to Common Toxicity Criteria version 3.0. Prostate-specific antigen failure was defined by Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2006 consensus definition. Results: Nine patients were treated from 2008 to 2010. The median follow-up was 31 months (range, 15-40 months). The mean preradiotherapy prostate-specific antigen was 4.3 ng/mL (range, 1.07-15.6 ng/mL). The median elapsed time between cryotherapy and IMRT was 20.5 months (range, 8.5-56.5 months). Biochemical control was achieved in 7 patients. Two patients developed distant metastases shortly after completion of radiotherapy. No patients experienced grade 3 or higher toxicities. Conclusions: Our results suggest that high-dose IMRT after cryotherapy failure is well tolerated, without severe morbidity. The results also showed that IMRT can render a significant number of patients biochemically free of disease after initial cryotherapy. High-dose IMRT should be considered as a treatment option for these potentially salvageable cases.",
keywords = "Cryotherapy, Intensity-modulated radiotherapy, Prostate cancer, Radiotherapy, Salvage therapy",
author = "Mehee Choi and Kim, {Choong R.} and Arthur Hung",
year = "2013",
month = "6",
doi = "10.1016/j.clgc.2012.09.003",
language = "English (US)",
volume = "11",
pages = "85--88",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy

AU - Choi, Mehee

AU - Kim, Choong R.

AU - Hung, Arthur

PY - 2013/6

Y1 - 2013/6

N2 - Background: To summarize our results of intensity-modulated radiation therapy (IMRT) for prostate adenocarcinoma after cryotherapy failure. Materials and Methods: Patients underwent IMRT with curative intent for biochemically recurrent prostate cancer after cryotherapy. Radiation was delivered to a minimum dose of 72 Gy (range, 72-81 Gy). Acute and late treatment-related gastrointestinal and genitourinary effects were scored according to Common Toxicity Criteria version 3.0. Prostate-specific antigen failure was defined by Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2006 consensus definition. Results: Nine patients were treated from 2008 to 2010. The median follow-up was 31 months (range, 15-40 months). The mean preradiotherapy prostate-specific antigen was 4.3 ng/mL (range, 1.07-15.6 ng/mL). The median elapsed time between cryotherapy and IMRT was 20.5 months (range, 8.5-56.5 months). Biochemical control was achieved in 7 patients. Two patients developed distant metastases shortly after completion of radiotherapy. No patients experienced grade 3 or higher toxicities. Conclusions: Our results suggest that high-dose IMRT after cryotherapy failure is well tolerated, without severe morbidity. The results also showed that IMRT can render a significant number of patients biochemically free of disease after initial cryotherapy. High-dose IMRT should be considered as a treatment option for these potentially salvageable cases.

AB - Background: To summarize our results of intensity-modulated radiation therapy (IMRT) for prostate adenocarcinoma after cryotherapy failure. Materials and Methods: Patients underwent IMRT with curative intent for biochemically recurrent prostate cancer after cryotherapy. Radiation was delivered to a minimum dose of 72 Gy (range, 72-81 Gy). Acute and late treatment-related gastrointestinal and genitourinary effects were scored according to Common Toxicity Criteria version 3.0. Prostate-specific antigen failure was defined by Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2006 consensus definition. Results: Nine patients were treated from 2008 to 2010. The median follow-up was 31 months (range, 15-40 months). The mean preradiotherapy prostate-specific antigen was 4.3 ng/mL (range, 1.07-15.6 ng/mL). The median elapsed time between cryotherapy and IMRT was 20.5 months (range, 8.5-56.5 months). Biochemical control was achieved in 7 patients. Two patients developed distant metastases shortly after completion of radiotherapy. No patients experienced grade 3 or higher toxicities. Conclusions: Our results suggest that high-dose IMRT after cryotherapy failure is well tolerated, without severe morbidity. The results also showed that IMRT can render a significant number of patients biochemically free of disease after initial cryotherapy. High-dose IMRT should be considered as a treatment option for these potentially salvageable cases.

KW - Cryotherapy

KW - Intensity-modulated radiotherapy

KW - Prostate cancer

KW - Radiotherapy

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=84876969408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876969408&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2012.09.003

DO - 10.1016/j.clgc.2012.09.003

M3 - Article

VL - 11

SP - 85

EP - 88

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 2

ER -